Bioreducible PEI-siRNA Nanocomplex for Liver Cancer Therapy: Transfection, Biodistribution, and Tumor Growth Inhibition In Vivo
Figure 4
(a) In vivo imaging of Cy5.5-labeled SS-PEI in HepG2 tumor bearing in nude mice at different time intervals; (b) tumor accumulation rate of Cy5.5-labeled SS-PEI after postinjection of its complexes at different time intervals; (c) organ distribution of Cy5.5-labeled SS-PEI after postinjection of its complexes at 24 h; (d) Ex vivo imaging of Cy5.5-labeled SS-PEI in organs after postinjection of its complexes at 24 h.
